Ozempic became the household name for GLP-1 weight loss despite never being approved for it. Ozempic is semaglutide licensed for type 2 diabetes; prescribing it for weight management is off-label. That distinction matters more than most people realise, because it affects insurance coverage, supply, and whether you are taking the right product at all. This guide covers the alternatives to Ozempic — starting with the one that is actually approved for what you want.

Quick Takeaway:

• Ozempic is FDA-approved for type 2 diabetes, not for weight management — using it for weight loss is off-label
• Wegovy is the same molecule, semaglutide, licensed specifically for chronic weight management
• Zepbound and Mounjaro contain tirzepatide, which has produced greater average weight loss in trials
• Oral options now exist: the Wegovy Pill and Foundayo (orforglipron)
• NovoCare® has offered Wegovy and Ozempic self-pay at $349/month against list prices of roughly $1,349 and $998

Looking for a Better Alternative?

Whichever medication you end up on, the provider determines cost and support. CoreAge Rx is our top-rated favorite for GLP-1 weight loss therapy, combining competitive pricing with exceptional customer service, faster medication delivery, and more comprehensive support resources.

Why we recommend CoreAge Rx:

• Lower monthly costs than most competitors ($179–$399 range)
• Faster prescription approval (typically 12–24 hours)
• More extensive provider support included at no extra charge
• Better medication availability during shortages
• Higher patient satisfaction scores (4.7/5)

New Patient Special: Save up to $200 on your first three months. Same-day prescription approval for qualifying patients. Rated 4.7/5 stars by verified customers. No insurance required.

Start Here: Wegovy Is the Approved Alternative

If you want semaglutide for weight loss, Wegovy is the product licensed for that purpose. It is the same active molecule as Ozempic, dosed to a higher maintenance level (2.4 mg) specifically for chronic weight management, and studied in trials with weight loss as the endpoint — producing around 15% mean loss at 68 weeks.

Why this matters practically:

• Insurance. A prior authorisation for weight management is far more likely to succeed for the drug licensed for that indication.
• Dosing. Wegovy titrates to a higher maintenance dose than Ozempic's diabetes schedule.
• Supply. Off-label demand for Ozempic contributed to shortages that affected diabetes patients who needed it.
• Documentation. Prescribing off-label is legal and common, but it puts you outside the licensed indication.

The Full Alternative Landscape

If You Want Better Results

Tirzepatide — sold as Zepbound for weight management and Mounjaro for diabetes — activates both the GLP-1 and GIP receptors rather than GLP-1 alone, and has produced greater average weight loss in clinical trials. If semaglutide has not delivered the response you hoped for, this is the standard next step to discuss with your prescriber.

See our semaglutide versus tirzepatide comparison for the full evidence.

If You Want to Avoid Injections

Two oral GLP-1 options now exist:

• Wegovy Pill (oral semaglutide), offered by Sesame from $149/month, Hims & Hers, ZAVA, and Boots
• Foundayo (orforglipron), Eli Lilly's oral GLP-1, distributed through LillyDirect, Amazon Pharmacy, telehealth providers, and pharmacies

For anyone whose barrier is the needle rather than the drug class, this changes the calculation entirely.

If Cost Is the Problem

Ozempic's list price is around $998 per month and Wegovy's around $1,349. Neither is what you need to pay.

Pro Tip: If you are currently paying retail for Ozempic, the single highest-value action available to you is checking whether your formulary covers Wegovy for weight management. The drug licensed for your indication is the one your insurer is most likely to approve.

If You Cannot Take a GLP-1 at All

Contraindications — medullary thyroid carcinoma history, MEN2, pregnancy — are absolute. Non-GLP-1 options remain:

• Orlistat (Xenical, Alli) — around 5% weight loss, available in the UK from £39.99/month
• Naltrexone/bupropion (Contrave, Mysimba) — around 5%–9%
• Phentermine/topiramate (Qsymia) — around 8%–10%
• Structured behavioural programmes — Second Nature reports 77.7% achieving at least 10% loss at twelve months
• Bariatric surgery — the most effective and durable option for severe obesity

See our alternative treatments guide.

Frequently Asked Questions

Is Ozempic approved for weight loss?

No. Ozempic is FDA-approved for type 2 diabetes. Prescribing it for weight management is off-label. Wegovy contains the same molecule, semaglutide, and is licensed specifically for chronic weight management.

What is the closest alternative to Ozempic for weight loss?

Wegovy — it is the same active ingredient, semaglutide, licensed for weight management and dosed to a higher maintenance level for that purpose.

Is Zepbound better than Ozempic?

Zepbound contains tirzepatide, a dual GIP/GLP-1 agonist that has produced greater average weight loss in trials — roughly 16.5%–22.4% over 72 weeks versus around 15% at 68 weeks for semaglutide 2.4 mg. Individual response varies substantially.

Is there a cheaper alternative to Ozempic?

Yes. Against a list price of around $998, NovoCare® has offered self-pay pricing at $349 per month, and bundled compounded telehealth programmes run roughly $179–$400 all in. Insurance coverage, where available, is cheaper than any of these.

Can I get semaglutide as a pill instead?

Yes. Oral semaglutide is available as the Wegovy Pill, offered by several telehealth providers and pharmacies. Eli Lilly's separate oral GLP-1, orforglipron, is marketed as Foundayo.

What if I can't take any GLP-1?

Non-GLP-1 prescription options include orlistat, naltrexone/bupropion, and phentermine/topiramate, producing roughly 5%–10% weight loss. Structured behavioural programmes and, for severe obesity, bariatric surgery are also established options.

Bottom Line

If you are taking Ozempic for weight loss, the most important alternative to consider is Wegovy — the same molecule, licensed for your actual indication, dosed for it, and far more likely to be covered by insurance for it.

If you want greater results, tirzepatide is the step up. If you want to avoid injections, oral GLP-1s now exist. If cost is the barrier, manufacturer self-pay at $349 and bundled programmes from $179 sit far below the $998–$1,349 list prices. And if a GLP-1 is not an option for you at all, several other treatments are.

CoreAge Rx offers semaglutide and tirzepatide with all-in monthly pricing from $179–$399 including medication, provider messaging, and titration support. 12–24 hour approvals. Save up to $200 on your first three months.

Medical disclaimer: Informational only, not medical advice. All medications discussed carry risks and contraindications. Off-label prescribing is a clinical decision for your prescriber. Consult a qualified healthcare professional before starting, switching, or stopping treatment.

Sources: FDA prescribing information for Ozempic, Wegovy, Zepbound, and Mounjaro; NovoCare® published self-pay pricing; Sesame published cost education; NICE obesity management guidance.

Date reviewed: August 2026